There were 668 patients who were enrolled in the study who were randomly assigned to either receive 1-mg/kg nivolumab plus 3-mg/kg ipilimumab with 480-mg nivolumab every 4 weeks for up to 2 years ...

Background: Nivolumab (nivo) 480 mg (Q4W) flat dose has already been assessed for safety compared to other drug dose regimens in clinical trials [1]. However, few data about melanoma patients treated ...

The recommended nivolumab dose for patients weighing 40 kg or more is 480 mg every 4 weeks or 240 mg every 2 weeks until disease recurrence or unacceptable toxicity for up to 1 year.

Patients in the control arm received cabozantinib-matched placebo in combination with nivolumab (3 mg/kg infusion, once every 3 weeks for 4 doses total) and ipilimumab (1 mg/kg infusion, once ...

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

Nivolumab (3 mg per kilogram of body weight) and ipilimumab (1 mg per kilogram) were administered once every 3 weeks for four cycles. Patients then received nivolumab maintenance therapy (480 mg ...

Those in the treatment arm received 1 mg/kg intravenous (IV) nivolumab with 3 mg/kg IV ipilimumab every 3 weeks for up to four doses, followed by single-agent IV nivolumab at 480 mg every 4 weeks ...

Patients were randomized 1:1 to tivozanib (0.89 mg per day, orally) plus nivolumab (480 mg every 4 weeks, intravenously) or tivozanib (1.34 mg per day, orally).

The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally advanced squamous cell carcinoma of the head and neck. "This is the ...

Opdivo is a prescription drug used to treat certain types of cancer. Learn about the drug’s dosages, form, strengths, and more.